Literature DB >> 18408000

Surface exposure of the HIV-1 env cytoplasmic tail LLP2 domain during the membrane fusion process: interaction with gp41 fusion core.

Lu Lu1, Yun Zhu, Jinghe Huang, Xi Chen, Hengwen Yang, Shibo Jiang, Ying-Hua Chen.   

Abstract

HIV-1 gp41 cytoplasmic tail (CT) is highly conserved among HIV-1 isolates, particularly the region designated lentivirus lytic peptide (LLP1-2), which includes two alpha-helical domains LLP1 and LLP2. Although the gp41 CT is recognized as a modulator of viral fusogenicity, little is known about the regulatory mechanism of this region in the viral fusion process. Here we report that anti-LLP1-2 and anti-LLP2 antibodies (IgG) inhibited HIV-1 Env-mediated cell fusion and bound to the interface between effector and target cells at a suboptimal temperature (31.5 degrees C), which slows down the fusion process and prolongs the fusion intermediate state. This suggests that LLP1-2, especially the LLP2 region located inside the viral membrane, is transiently exposed on the membrane surface during the fusion process. Synthetic LLP2 peptide could bind to the gp41 six-helix bundle core with high binding affinity. These results suggest that the gp41 CT may interact with the gp41 core, via the surface-exposed LLP2 domain, to regulate Env-mediated membrane fusion.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18408000      PMCID: PMC2423246          DOI: 10.1074/jbc.M801083200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  Protein design of an HIV-1 entry inhibitor.

Authors:  M J Root; M S Kay; P S Kim
Journal:  Science       Date:  2001-02-02       Impact factor: 47.728

2.  Cellular membrane-binding ability of the C-terminal cytoplasmic domain of human immunodeficiency virus type 1 envelope transmembrane protein gp41.

Authors:  S S Chen; S F Lee; C T Wang
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

3.  Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein.

Authors:  Terri G Edwards; Stéphanie Wyss; Jacqueline D Reeves; Susan Zolla-Pazner; James A Hoxie; Robert W Doms; Frédéric Baribaud
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

Review 4.  Mechanisms of viral membrane fusion and its inhibition.

Authors:  D M Eckert; P S Kim
Journal:  Annu Rev Biochem       Date:  2001       Impact factor: 23.643

5.  SIV gp41 binds to membranes both in the monomeric and trimeric states: consequences for the neuropathology and inhibition of HIV infection.

Authors:  S G Peisajovich; Y Shai
Journal:  J Mol Biol       Date:  2001-08-10       Impact factor: 5.469

6.  Structure and interaction with membrane model systems of a peptide derived from the major epitope region of HIV protein gp41: implications on viral fusion mechanism.

Authors:  L M Contreras; F J Aranda; F Gavilanes; J M González-Ros; J Villalaín
Journal:  Biochemistry       Date:  2001-03-13       Impact factor: 3.162

7.  The polar region consecutive to the HIV fusion peptide participates in membrane fusion.

Authors:  S G Peisajovich; R F Epand; M Pritsker; Y Shai; R M Epand
Journal:  Biochemistry       Date:  2000-02-22       Impact factor: 3.162

8.  Evidence for a stable interaction of gp41 with Pr55(Gag) in immature human immunodeficiency virus type 1 particles.

Authors:  D J Wyma; A Kotov; C Aiken
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

9.  Domains in the simian immunodeficiency virus gp41 cytoplasmic tail required for envelope incorporation into particles.

Authors:  C C Celma; J M Manrique; J L Affranchino; E Hunter; S A González
Journal:  Virology       Date:  2001-05-10       Impact factor: 3.616

10.  Important changes in biochemical properties and function of mutated LLP12 domain of HIV-1 gp41.

Authors:  Yun Zhu; Lu Lu; Lijun Chao; Ying-Hua Chen
Journal:  Chem Biol Drug Des       Date:  2007-09-10       Impact factor: 2.817

View more
  29 in total

1.  Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane protein.

Authors:  Thomas S Postler; José M Martinez-Navio; Eloísa Yuste; Ronald C Desrosiers
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Enhanced central nervous system transduction with lentiviral vectors pseudotyped with RVG/HIV-1gp41 chimeric envelope glycoproteins.

Authors:  Antonio Trabalza; Ioanna Eleftheriadou; Argyro Sgourou; Ting-Yi Liao; Petros Patsali; Heyne Lee; Nicholas D Mazarakis
Journal:  J Virol       Date:  2013-12-26       Impact factor: 5.103

3.  Highly conserved structural properties of the C-terminal tail of HIV-1 gp41 protein despite substantial sequence variation among diverse clades: implications for functions in viral replication.

Authors:  Jonathan D Steckbeck; Jodi K Craigo; Christopher O Barnes; Ronald C Montelaro
Journal:  J Biol Chem       Date:  2011-06-09       Impact factor: 5.157

4.  Identification of a gp41 core-binding molecule with homologous sequence of human TNNI3K-like protein as a novel human immunodeficiency virus type 1 entry inhibitor.

Authors:  Yun Zhu; Lu Lu; Liling Xu; Hengwen Yang; Shibo Jiang; Ying-Hua Chen
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

Review 5.  HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation.

Authors:  Mary Ann Checkley; Benjamin G Luttge; Eric O Freed
Journal:  J Mol Biol       Date:  2011-07-22       Impact factor: 5.469

Review 6.  Targeting HIV-1 gp41-induced fusion and pathogenesis for anti-viral therapy.

Authors:  Himanshu Garg; Mathias Viard; Amy Jacobs; Robert Blumenthal
Journal:  Curr Top Med Chem       Date:  2011-12       Impact factor: 3.295

7.  The membrane-spanning domain of gp41 plays a critical role in intracellular trafficking of the HIV envelope protein.

Authors:  Kosuke Miyauchi; A Rachael Curran; Yufei Long; Naoyuki Kondo; Aikichi Iwamoto; Donald M Engelman; Zene Matsuda
Journal:  Retrovirology       Date:  2010-11-13       Impact factor: 4.602

Review 8.  The tale of the long tail: the cytoplasmic domain of HIV-1 gp41.

Authors:  Thomas S Postler; Ronald C Desrosiers
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

9.  ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation.

Authors:  Hongtao Wang; Zhi Qi; Angi Guo; Qinchao Mao; Hong Lu; Xiuli An; Chenglai Xia; Xiaojuan Li; Asim K Debnath; Shuguang Wu; Shuwen Liu; Shibo Jiang
Journal:  Antimicrob Agents Chemother       Date:  2009-09-28       Impact factor: 5.191

10.  Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies.

Authors:  Tessa Dieltjens; Leo Heyndrickx; Betty Willems; Elin Gray; Lies Van Nieuwenhove; Katrijn Grupping; Guido Vanham; Wouter Janssens
Journal:  Retrovirology       Date:  2009-12-14       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.